Anti-VEGF therapies have become a major treatment modality in the daily care of wet AMD to suppress the growth of neovessels, which invade the retina from the underlying choroid, located below the retinal pigment epithelium (RPE) [3, 5]. This evidence concerns the gene VEGFA and wet macular degeneration.